Download PDF
Int J Angiol 2021; 30(02): 155-159
DOI: 10.1055/s-0040-1721403
Rapid Communication

Will Remdesivir Reshape Cardiovascular Practice in COVID 19 Era?

A. Mohammed Idhrees 
1   Institute of Cardiac and Aortic Disorders, SRM Institutes for Medical Science (SIMS Hospital), Chennai, Tamil Nadu, India
,
Prasanna Karthik Suthakaran
2   Department of General Medicine, Saveetha Medical College Hospital, Chennai, Tamil Nadu, India
,
George Jose Valooran
3   Department of CVTS, Rajagiri Hospital, Kochi, Kerala, India
,
Mohamad Bashir
4   Department of Vascular and Endovascular Surgery, Royal Blackburn Teaching Hospital, Blackburn, Lancashire, United Kingdom of Great Britain and Northern Ireland
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Infection with the novel coronavirus, SARS-CoV2, produces the clinical syndrome COVID-19. COVID-19 is a systemic illness inducing hyperinflammation and cytokine storm affecting multiple organs including the myocardium which is reflected in elevated cardiac biomarkers such as troponin, lactate dehydrogenase, and creatinine kinase MB. Furthermore, COVID-19 has been implicated in increased predilection to thromboembolic phenomena. Hence, mortality in patients with associated cardiovascular disease has been higher compared with the cohort with no cardiovascular comorbidity. It is entirely unknown how remdesivir will change the facet of cardiovascular medicine and surgery. In the present constantly changing climate, this review of remdesivir and its association with cardiovascular disease is comprehensive as of June 17, 2020 and it highlights the science behind this drug and its potential implications to cardiovascular practice.

Keywords

remdesivir - COVID-19 - coronavirus - SARS-CoV2 - cardiovascular surgery - cardiovascular medicine


Publication History

Article published online:
03 December 2020

© 2020. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Wang Y, Zhang D, Du G. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. [published correction appears in Lancet. 2020 May 30;395(10238):1694]. Lancet 2020; 395 (10236): 1569-1578
    CrossrefPubMedGoogle Scholar
  • 2 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323 (13) 1239-1242
    CrossrefPubMedGoogle Scholar
  • 3 Richardson S, Hirsch JS, Narasimhan M. et al; the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020; 323 (20) 2052-2059
    CrossrefPubMedGoogle Scholar
  • 4 Yang J, Zheng Y, Gou X. et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91-95
    CrossrefPubMedGoogle Scholar
  • 5 Wang D, Hu B, Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323 (11) 1061-1069
    CrossrefPubMedGoogle Scholar
  • 6 Guo J, Huang Z, Lin L, Lv J. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc 2020; 9 (07) e016219
    CrossrefPubMedGoogle Scholar
  • 7 Clerkin KJ, Fried JA, Raikhelkar J. et al. Covid-19 and cardiovascular disease. Circulation 2020; 141 (20) 1648-1655
    CrossrefPubMedGoogle Scholar
  • 8 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054-1062
    CrossrefPubMedGoogle Scholar
  • 9 Xu Z, Shi L, Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8 (04) 420-422
    CrossrefPubMedGoogle Scholar
  • 10 Shi S, Qin M, Shen B. et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020; 5 (07) 802-810
    CrossrefPubMedGoogle Scholar
  • 11 Guo T, Fan Y, Chen M. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; 5 (07) 811-818
    CrossrefPubMedGoogle Scholar
  • 12 Wan S, Xiang Y, Fang W. et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol 2020; 92 (07) 797-806
    CrossrefPubMedGoogle Scholar
  • 13 Aboughdir M, Kirwin T, Abdul Khader A, Wang B. Prognostic value of cardiovascular biomarkers in COvid-19: a review. Viruses 2020; 12 (05) 527
    CrossrefPubMedGoogle Scholar
  • 14 Klok FA, Kruip MJHA, van der Meer NJM. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-147
    CrossrefPubMedGoogle Scholar
  • 15 Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020; 7 (06) e438-e440
    Google Scholar
  • 16 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18 (04) 844-847
    CrossrefPubMedGoogle Scholar
  • 17 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506
    CrossrefPubMedGoogle Scholar
  • 18 Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18 (05) 1094-1099
    CrossrefPubMedGoogle Scholar
  • 19 Gordon CJ, Tchesnokov EP, Woolner E. et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 2020; 295 (20) 6785-6797
    CrossrefPubMedGoogle Scholar
  • 20 Eastman RT, Roth JS, Brimacombe KR. et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci 2020; 6 (05) 672-683
    CrossrefPubMedGoogle Scholar
  • 21 Lo MK, Jordan R, Arvey A. et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep 2017; 7: 43395
    CrossrefPubMedGoogle Scholar
  • 22 de Wit E, Feldmann F, Cronin J. et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A 2020; 117 (12) 6771-6776
    CrossrefPubMedGoogle Scholar
  • 23 Wang M, Cao R, Zhang L. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30 (03) 269-271
    CrossrefPubMedGoogle Scholar
  • 24 Grein J, Ohmagari N, Shin D. et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382 (24) 2327-2336
    CrossrefPubMedGoogle Scholar
  • 25 Beigel JH, Tomashek KM, Dodd LE. et al; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19-preliminary report. N Engl J Med 2020; DOI: 10.1056/NEJMoa2007764.
    CrossrefPubMedGoogle Scholar
  • 26 Accessed June 6, 2020 at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment
  • 27 Accessed June 6, 2020 at: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines-covid-19
  • 28 Siegel D, Hui HC, Doerffler E. et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem 2017; 60 (05) 1648-1661
    CrossrefPubMedGoogle Scholar
  • 29 McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infect Dis 2020; 7 (04) a105
    CrossrefPubMedGoogle Scholar
  • 30 Yang K. What do we know about remdesivir drug interactions?. Clin Transl Sci 2020; 13 (05) 842-844
    PubMedGoogle Scholar
  • 31 Akhmerov A, Marbán E. COVID-19 and the heart. Circ Res 2020; 126 (10) 1443-1455
    CrossrefPubMedGoogle Scholar